You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ipilimumab

Showing 51 - 75 of 387
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Hormone-Sensitive Prostate Cancer Trial in Saint Louis (biological, drug, device, procedure)

Completed
  • Metastatic Hormone-Sensitive Prostate Cancer
  • PROSTVAC-V
  • +9 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Aug 3, 2022

Lung Cancer, SCLC Trial in United States (Nivolumab, Plinabulin, Ipilimumab)

Recruiting
  • Lung Cancer
  • SCLC
  • Duarte, California
  • +7 more
Jan 18, 2023

Locally Advanced Pancreatic Cancer (LAPC) Trial in Herlev (Gemcitabine, Nab-paclitaxel, Nivolumab)

Recruiting
  • Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer
  • Herlev, Denmark
    Herlev & Gentofte University Hospital, Denmark
Oct 13, 2022

Colon Carcinoma Trial in Netherlands (Nivolumab, Ipilimumab, Celecoxib 200mg)

Recruiting
  • Colon Carcinoma
  • Amsterdam, Netherlands
  • +5 more
Jan 23, 2023

Uveal Melanoma, Liver Metastases Trial in Gothenburg (Isolated hepatic perfusion, Ipilimumab, Nivolumab)

Recruiting
  • Uveal Melanoma
  • Liver Metastases
  • Isolated hepatic perfusion
  • +2 more
  • Gothenburg, Sweden
    Sahlgrenska University Hospital
May 3, 2022

Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

Recruiting
  • Acute Bilineal Leukemia
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 24, 2023

Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Recurrent Platinum-Resistant Ovarian Carcinoma Trial in

Recruiting
  • Metastatic Malignant Solid Neoplasm
  • +3 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +2 more
  • Bethesda, Maryland
  • +4 more
Aug 16, 2022

NSCLC Trial in Singapore (Ipilimumab, Nivolumab)

Terminated
  • Non-Small Cell Lung Cancer
  • Singapore, Singapore
  • +2 more
Jun 10, 2022

Melanoma Trial in Worldwide (encorafenib, binimetinib, pembrolizumab)

Recruiting
  • Melanoma
  • Siena, Toscana, Italy
  • +11 more
Jun 23, 2023

Thyroid Cancer Trial in Boston (Nivolumab, Ipilimumab)

Active, not recruiting
  • Thyroid Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Feb 18, 2022

Advanced Solid Tumors Trial in Grand Rapids, Houston, San Antonio (CPI-1205, ipilimumab)

Completed
  • Advanced Solid Tumors
  • Grand Rapids, Michigan
  • +2 more
May 16, 2022

Kidney Cancer Trial in Boston (NeoVax, Ipilimumab)

Recruiting
  • Kidney Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 22, 2022

Pituitary, Pituitary Tumor, Pituitary Carcinoma Trial in United States (Ipilimumab, Nivolumab)

Recruiting
  • Pituitary
  • +3 more
  • Los Angeles, California
  • +7 more
Oct 31, 2022

Advanced Malignant Solid Tumor, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8 Trial

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +8 more
  • Imatinib Mesylate
  • Ipilimumab
  • Houston, Texas
    M D Anderson Cancer Center
Aug 1, 2022

Basal Cell Carcinoma Trial in Baltimore (Nivolumab, Ipilimumab, Relatlimab)

Recruiting
  • Basal Cell Carcinoma
  • Baltimore, Maryland
    Johns Hopkins Hospital
Mar 10, 2022

Advanced Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma Trial in Duarte (Clostridium

Active, not recruiting
  • Advanced Renal Cell Carcinoma
  • +5 more
  • Clostridium butyricum CBM 588 Probiotic Strain
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Oct 12, 2022

Pancreatic Cancer Trial in Herlev (Nivolumab, Ipilimumab, Tocilizumab)

Terminated
  • Pancreatic Cancer
  • Herlev, Denmark
    Herlev & Gentofte University Hospital, Denmark
Mar 15, 2022

Metastatic Tumor, Advanced Tumor Trial in France (Pexa-Vec, Ipilimumab)

Completed
  • Metastatic Tumor
  • Advanced Tumor
  • Pexa-Vec
  • Ipilimumab
  • Bordeaux, France
  • +4 more
Jul 22, 2022

Relapsed DLBCL, Refractory DLBCL Trial in New York (Ipilimumab, Nivolumab)

Completed
  • Relapsed Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Apr 4, 2022

Head Neck Cancer Trial in Boston (Nivolumab, Ipilimumab, Standard of Care Surgery)

Active, not recruiting
Has Results
  • Head and Neck Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Feb 22, 2022

Metastatic Colorectal Cancer Trial in France (Nivolumab, Ipilimumab)

Recruiting
  • Metastatic Colorectal Cancer
  • Besançon, France
  • +5 more
May 6, 2022

Malignant Melanoma Stage III Trial in Worldwide (Ipilimumab, Nivolumab, Surgery)

Active, not recruiting
  • Malignant Melanoma Stage III
  • Ipilimumab
  • +4 more
  • Sydney, New South Wales, Australia
  • +3 more
Apr 14, 2022

Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors, SMARCA4-deficient Primary CNS Malignant

Recruiting
  • Atypical Teratoid Rhabdoid Tumor
  • +6 more
  • Boston, Massachusetts
  • +1 more
Jan 23, 2023

Hepatocellular Carcinoma, HCC Trial in Orange (Nivolumab, Ipilimumab, Cabozantinib)

Recruiting
  • Hepatocellular Carcinoma
  • HCC
  • Orange, California
    Chao Family Comprehensive Cancer Center, University of Californi
Apr 4, 2022

Melanoma Trial in Houston (ABI-007, Ipilimumab, Phone Call)

Completed
Has Results
  • Melanoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jan 12, 2022